

REMARKS

Status of the Claims

Claims 59-64 will be pending following entry of the present amendment. Claims 1-8, 14-20, and 53 have been cancelled without prejudice to or disclaimer of the subject matter contained therein. New claims 61-64 have been added. The new claims are fully supported by the originally filed specification and claims. No new matter has been added by way of amendment. The Examiner is respectfully requested to withdraw the rejections and allow claims 59-64. In any event, the Examiner is requested to enter the above amendments for the purposes of further prosecution. These amendments were not made earlier because Applicants earnestly believe that the specification is enabling for the breadth of the claims as originally drafted.

The Rejection under 35 U.S.C. § 112, Second Paragraph, Should be Withdrawn

The rejection of claims 1-8, 14, and 16-18 under 35 U.S.C. §112, second paragraph, has been maintained. Claims 1-8, 14, and 16-18 have been cancelled to expedite prosecution, thereby rendering the rejection of these claims moot. Accordingly, all grounds for rejection under 35 U.S.C. §112, second paragraph have been obviated. Reconsideration and withdrawal of the rejection are respectfully requested.

The Rejections under 35 U.S.C. §112, First Paragraph, Should be Withdrawn

The rejection of claim 1 under 35 U.S.C. §112, first paragraph, for lack of enablement has been maintained. Claim 1 has been cancelled to expedite prosecution, thereby obviating the rejection.

The rejection of claims 1-8, 14, and 16-18 under 35 U.S.C. §112, first paragraph, on the grounds that they lack a sufficient written description has been maintained. Claims 1-8, 14, and 16-18 have been cancelled to expedite prosecution, thereby rendering the rejection of these claims moot.

In view of the above amendments, all grounds for rejection under 35 U.S.C. §112, first paragraph, have been overcome. Reconsideration and withdrawal of the rejections are respectfully requested.

CONCLUSION

It is believed that the current application is now in condition for allowance. Early notice to this effect is solicited. If, in the opinion of the Examiner, an interview would expedite prosecution, the Examiner is invited to call the undersigned, who can be reached at (919) 483-1467.

Respectfully submitted,

/Kathryn L. Coulter/

Kathryn L. Coulter
Attorney for Applicant
Reg. No. 45,889

Date: 6/30/2010
Customer No. 23347
GlaxoSmithKline
Global Patents
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-1467
Facsimile: (919) 483-7988